Company Profiles

driven by the PitchBook Platform

Neotropix

Description

Developer of deliverable oncolytic viruses for the treatment of cancer. The company develops viruses for oncology applications and offers NTX010, a cancer fighting virus.

2003

Founded

PRIVATE

Status

1-10

Employees

Series B

Latest Deal Type

$1.4M

Latest Deal Amount

$17.4M

Total Amount Raised

Description

Developer of deliverable oncolytic viruses for the treatment of cancer. The company develops viruses for oncology applications and offers NTX010, a cancer fighting virus.

Website:

www.neotropix.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Delivery
Drug Discovery

Primary Office

351 Phoenixville Pike Malvern, PA 19355United States +1 (617) 460-1200
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Neotropix's full profile, request a free trial.

Neotropix Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Neotropix Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Neotropix Investors (3)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Quaker PartnersVenture CapitalMinority000 0000000 0000
The Aurora FundsVenture CapitalMinority000 0000000 0000
VIMAC VenturesVenture CapitalMinority000 0000000 0000
Quaker Partners Venture Capital
The Aurora Funds Venture Capital
VIMAC Ventures Venture Capital

Neotropix Board Members (2)

NameRepresentingRoleSinceContact
Info
Christopher Kroeger MDThe Aurora FundsPartner000 0000
Sena Biswas Ph.DVIMAC VenturesManaging Director, Life Sciences000 0000
Christopher Kroeger MD Partner The Aurora Funds
Sena Biswas Ph.D Managing Director, Life Sciences VIMAC Ventures
Request full access to PitchBook